Jun 22, 2015 | News
Phase 2a Clinical Trial of a Novel Nuclear Receptor Agonist in Alzheimer’s patients expected to initiate in 3Q2015. Read More
Jun 8, 2015 | News
T3D Therapeutics, Inc. has been selected by the Alzheimer’s Association to present pre-clinical results of T3D-959 at the upcoming Alzheimer’s Association International Conference (AAIC) in Washington, DC, July 18-23, 2015. The poster presentation will provide details...